-transparent.png){kind=logo}
A series of substituted azabischalcones Ia-Ip, monochalcone II and dihydroxyderivative III has been prepared and examined for their in vitro activity against Mycobacterium tuberculosis, Mycobacterium kansasii, Mycobacterium avium, Mycobacterium fortuitum as well as INH-resistant strains. Several compounds under study have the same activity as INH and greater than PAS, Contebene, Ethionamide. The results are summarized in Table 1. In the case of compound Ie, its in vivo activity was studied against M. tuberculosis as well (see Table 2). The toxicity of compounds under study is very low--2000 mg/kg/mouse.
Related Publications
V Kozmík, and
P Lhoták, and
Z Odlerová, and
J Palecek
October 2010,
Bioorganic & medicinal chemistry letters,
V Kozmík, and
P Lhoták, and
Z Odlerová, and
J Palecek
March 2020,
European journal of medicinal chemistry,
V Kozmík, and
P Lhoták, and
Z Odlerová, and
J Palecek
September 1988,
Die Pharmazie,
V Kozmík, and
P Lhoták, and
Z Odlerová, and
J Palecek
February 1989,
Die Pharmazie,
V Kozmík, and
P Lhoták, and
Z Odlerová, and
J Palecek
October 2012,
Bioorganic & medicinal chemistry letters,
V Kozmík, and
P Lhoták, and
Z Odlerová, and
J Palecek
January 2019,
Current topics in medicinal chemistry,
V Kozmík, and
P Lhoták, and
Z Odlerová, and
J Palecek
February 1990,
Die Pharmazie,
V Kozmík, and
P Lhoták, and
Z Odlerová, and
J Palecek
August 2006,
Bioorganic & medicinal chemistry,
V Kozmík, and
P Lhoták, and
Z Odlerová, and
J Palecek
November 2003,
Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti,
V Kozmík, and
P Lhoták, and
Z Odlerová, and
J Palecek
September 1985,
Ceskoslovenska farmacie,
